Bone Marrow Transplantation
Hematology
Dr. Matt E. Kalaycio, MD
|
|
Give Review
Matt Kalaycio works in the field of Hematology. He went to West Virginia University School of Medicine. He received awards:"America's Top Doctors", "America's Top Doctors for Cancer", "CMS Meaningful Use Stage 1 Certification" and "Northern Ohio Live". Matt E. Kalaycio, MD is also a published MD. He has 56 paper published. The most recent paper is: G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Association of socioeconomic status with long-term outcomes in 1-year survivors of allogeneic hematopoietic Cell transplantation.
- Impaired right ventricular-pulmonary vascular function in Myeloproliferative neoplasms.
- Racial differences in allogeneic hematopoietic Cell transplantation outcomes among African Americans and whites.
- Cyclosporine in combination with mycophenolate mofetil versus methotrexate for Graft versus host disease prevention in myeloablative HLA-identical sibling donor alloge...
- Impact of vancomycin-resistant enterococcal bacteremia on outcome during Acute myeloid leukemia induction therapy.
- Outcomes after autologous SCT in Lymphoma patients grouped by weight.
- Comparison of Outcomes of Allogeneic Transplantation for CML with Cyclophosphamide in Combination with Intravenous Busulfan, Oral Busulfan or TBI.
- Synergistic Effect of Major Histocompatibility Complex Class I-Related Chain A and Human Leukocyte Antigen-DPB1 Mismatches in Association with Acute Graft-versus-Host ...
- Maximizing the benefits of mycophenolate mofetil as Graft-versus-host disease prophylaxis.
- Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic Cell transplantation.
- Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic Cell transplantation.
- Fine-mapping of HLA associations with chronic lymphocytic Leukemia in US populations.
- Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.
- Spontaneous recovery of severe nilotinib-induced bone marrow aplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia.
- Outcomes of Human Leukocyte Antigen-Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Co...
- Clinicopathologic and molecular characterization of Myeloid neoplasms harboring isochromosome 17(q10).
- Validation and refinement of the disease risk index for allogeneic stem Cell transplantation: a study from the CIBMTR.
- Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet Syndrome that was refractory to 5-azacitidine.
- Reduced-intensity hematopoietic Cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow tran...
- Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigen-Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?
- Long-term follow-up of a prospective randomized trial comparing CYA and MTX with CYA and mycophenolate mofetil for GVHD prophylaxis in myeloablative sibling donor hema...
- Predictive Factors for Latency Period and a Prognostic Model for Survival in Patients with Therapy-related AML.
- Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory Chronic lymphocytic leukaemia (CLL).
- Fludarabine: a review of the clear benefits and potential harms.
- Better Leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared to TBI.
- Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.
- Outcomes in obese and overweight Acute myeloid leukemia patients receiving chemotherapy dosed according to actual body weight.
- Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic Syndromes (MDS).
- Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myelo...
- Salvage Second Hematopoietic Cell Transplantation in Myeloma.
- Treatment of adults with Acute lymphoblastic leukemia: Do the specifics of the regimen matter?: Results from a prospective randomized trial.
- Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in Acute myeloid leukemia.
- Development of a modified surveillance definition of central line-associated bloodstream infections for patients with hematologic malignancies.
- Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis.
- Targeted therapy for patients with chronic myeloid Leukemia: clinical trial experience and challenges in inter-trial comparisons.
- Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed Acute lymphoblastic leukemia.
- A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary Acute myeloid leukemia.
- Allogeneic hematopoietic cell transplant for prolymphocytic Leukemia.
- Bendamustine: a new look at an old drug.
- Time from diagnosis to treatment initiation predicts survival in younger, but not older, Acute myeloid leukemia patients.
- A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic Syndromes.
- High disease burden is associated with poor outcomes for patients with Acute myeloid leukemia not in remission who undergo unrelated donor cell transplantation.
- Alteplase for central catheter clearance: 1 mg/mL versus 2 mg/2 mL.
- A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory Acute lymphoblastic leukemia.
- BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B Cells.
- Hemorrhagic ascites secondary to endometriosis.
- Clinical status of the new cytoprotective agent, amifostine.
- Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine (BCNU).
- Survival after ABO-incompatible allogeneic bone marrow transplant after a preparative regimen of busulfan and cyclophosphamide.
- G-CSF post-autologous progenitor Cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day.
- Clinical decision-making: Acute myelogenous leukemia in first complete remission.
- High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor Cell rescue for metastatic breast cancer.
- Eosinophilia after allogeneic bone marrow transplantation using the busulfan and cyclophosphamide preparative regimen.
- Accelerated Phase CML: Outcomes in Newly Diagnosed vs. Progression From Chronic Phase.
- Perspectives in Oncology Drug Pricing.
Schools
West Virginia University School Of Medicine
Mercy Hosptial Of Pittsburgh
Mercy Hospital
Cleveland Clin Found
Procedures Preformed
- Bone Marrow Transplant
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- HPC Transplantation (Stem Cell Transplant)
- Plasmapheresis
- View All
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Basal Cell Carcinoma
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- CareSource
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Commercial Insurance Company
- Coventry Health Care
- Frontpath Health Coalition
- Golden Rule
- Medicare Advantage PFFS
- HealthSmart
- Choice Care PPO
- Kaiser Permanente
- Mail Handlers Benefit Plan (MHBP)
- Medicaid
- Medical Mutual of Ohio POS
- Medicare MCR
- Meritain Health
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Paramount
- Simplifi
- State Farm
- Thrivent Financial
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- UPMC Health Plan
- WellCare
- Wells Fargo Insurance
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- CMS Meaningful Use Stage 1 Certification
- Northern Ohio Live
Education
-
Cleveland Clinic Foundation -
University of Pittsburgh Medical Center-Mercy Hospital -
West Virginia University School of Medicine
Hospital
-
Cleveland Clinic
Drug Facts
| NPI NUMBER | 1710943006 | |
| NPPES Provider LastName | KALAYCIO | |
| NPPES Provider FirstName | MATT | |
| NPPES Provider ZIPCode | 441950001 | |
| NPPES Provider State | OH | |
| Specialty Description | Internal Medicine | |
| Total Claim Count | 701.0 | |
| Distinct Opioid Count | 4.0 | |
| Opioid Claim Count | 56.0 | |
| Percent Opioid Claims | 7.99 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710943006 |
| Last Name Of The Provider | KALAYCIO |
| First Name Of The Provider | MATT |
| View All |
Similar Doctors
|
Dr. Paula Silverman, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin J. Kerwin, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Clark W. Distelhorst, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Douglas W. Warden, MD |
|
|
Dr. Michael C. Nemunaitis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heesun Rogers, MD |
|
|
Dr. Roy L. Silverstein, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Mir Y. Ali, MD |
|
|
Dr. Mark Cooper, MD |